



ELSEVIER

Experimental Hematology 2021;000:1–13

## Chronic lymphocytic leukemia–like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia

Gonzalo Blanco<sup>a,b</sup>, Anna Puiggros<sup>a,b</sup>, Barbara Sherry<sup>c,d,e</sup>, Lara Nonell<sup>f</sup>, Xavier Calvo<sup>a,b</sup>, Eulàlia Puigdecanel<sup>f</sup>, Pui Yan Chiu<sup>c</sup>, Yasmine Kieso<sup>g</sup>, Gerardo Ferrer<sup>g</sup>, Florencia Palacios<sup>g</sup>, Magdalena Arnal<sup>f</sup>, María Rodríguez-Rivera<sup>a,b</sup>, Eva Gimeno<sup>h,i</sup>, Eugènia Abella<sup>h,i</sup>, Kanti R. Rai<sup>d,g</sup>, Pau Abrisqueta<sup>j</sup>, Francesc Bosch<sup>j</sup>, Alexandre Calon<sup>k</sup>, Ana Ferrer<sup>a,b</sup>, Nicholas Chiorazzi<sup>d,e,g</sup>, and Blanca Espinet<sup>a,b</sup>

<sup>a</sup>Laboratori de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia, Hospital del Mar, Barcelona, Spain; <sup>b</sup>Grup de Recerca Translacional en Neoplàsies Hematològiques, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; <sup>c</sup>Center for Immunology and Inflammation, The Feinstein Institute for Medical Research, Manhasset, NY; <sup>d</sup>Department of Medicine, Hofstra Northwell School of Medicine, Hempstead, NY; <sup>e</sup>Department of Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, NY; <sup>f</sup>MARGenomics, IMIM, Barcelona, Spain; <sup>g</sup>Karches Center for Oncology Research, The Feinstein Institute for Medical Research, Manhasset, NY; <sup>h</sup>Servei d'Hematologia, Hospital del Mar-IMIM, Barcelona, Spain; <sup>i</sup>Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques, Cancer Research Program, IMIM-Hospital del Mar, Barcelona, Spain; <sup>j</sup>Servei d'Hematologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain; <sup>k</sup>Laboratori de Recerca Translacional en Microambient Tumoral, Cancer Research Program, IMIM, Barcelona, Spain

(Received 27 March 2020; revised 30 December 2020; accepted 31 December 2020)

Several studies in chronic lymphocytic leukemia (CLL) patients have reported impaired immune cell functions, which contribute to tumor evasion and disease progression. However, studies on CLL-like monoclonal B-cell lymphocytosis (MBL) are scarce. In the study described here, we characterized the immune environment in 62 individuals with clinical MBL, 56 patients with early-stage CLL, and 31 healthy controls. Gene expression arrays and quantitative reverse transcription polymerase chain reaction were performed on RNA from CD4<sup>+</sup> peripheral blood cells; serum cytokines were measured with immunoassays; and HLA-DR expression on circulating monocytes, as well as the percentages of Th1, cytotoxic, exhausted, and effector CD4<sup>+</sup> T cells, were evaluated by flow cytometry. In addition, cell cultures of clonal B cells and CD14-enriched or -depleted cell fractions were performed. Strikingly, MBL and early-stage CLL differed in pro-inflammatory signatures. An increased inflammatory drive orchestrated mainly by monocytes was identified in MBL, which exhibited enhanced phagocytosis, pattern recognition receptors, interleukin-8 (IL8), HMGB1, and acute response signaling pathways and increased pro-inflammatory cytokines (in particular IL8, interferon  $\gamma$  [IFN $\gamma$ ], and tumor necrosis factor  $\alpha$ ). This inflammatory signature was diminished in early-stage CLL (reduced IL8 and IFN $\gamma$  levels, IL8 signaling pathway, and monocytic HLA-DR expression compared with MBL), especially in those patients with mutations in IGHV genes. Additionally, CD4<sup>+</sup> T cells of MBL and early-stage CLL exhibited a similar upregulation of Th1 and cytotoxic genes and expanded CXCR3<sup>+</sup>

GB and AP contributed equally to this work. GB, AP, and BE designed the research study, analyzed all data, and wrote the article. GB and AP processed the samples and performed the experiments. BS, GF, FP, and NC participated in the design and interpretation of serum studies. NC made major contributions in the discussion of the results and writing of the article. LN and MA analyzed raw gene expression data. XC and AF helped in the design and analysis of flow cytometry experiments. EP contributed to performing microarray and qRT-PCR assays. PYC contributed to performing cytokine immunoassays. YK helped with data management. MRR contributed

to sample processing. EG, EA, KRR, PA, and FB provided patient data and samples. AC helped to perform cell culture assays. All authors read the last version of the article.

Offprint requests to: Blanca Espinet, Laboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Pg. Marítim 25 –29, 08003 Barcelona, Spain; E-mail: [bespinet@parcdesalutmar.cat](mailto:bespinet@parcdesalutmar.cat)

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.exphem.2020.12.007>.

and perforin<sup>+</sup> CD4<sup>+</sup> T cells, as well as PD1<sup>+</sup> CD4<sup>+</sup> T cells, compared with controls. Cell culture assays disclosed tumor-supporting effects of monocytes similarly observed in MBL and early-stage CLL. These novel findings reveal differences in the inflammatory environment between MBL and CLL, highlighting an active role for antigen stimulation in the very early stages of the disease, potentially related to malignant B-cell transformation. © 2021 ISEH – Society for Hematology and Stem Cells. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Several alterations have been described in T cells of patients with chronic lymphocytic leukemia (CLL), presumably a consequence of chronic exposure to tumor cells [1–8]. Additionally, an elevated number of monocytes have been detected in peripheral blood (PB) of patients with the disease, exhibiting deregulated genes involved in phagocytosis and inflammation [9]. Serum cytokine levels have also been described to be altered in CLL [10], and increased levels of some cytokines such as CC chemokine ligand 3 (CCL3) and IL8 have been associated with a worse outcome [11,12].

CLL-like monoclonal B-cell lymphocytosis (MBL) is defined as the presence of a clonal population of B lymphocytes in PB ( $<5 \times 10^9/L$ ) having a phenotype consistent with CLL, without other clinical features of the disease. Its frequency increases with age, being present in >50% of people >90 years of age. Those cases with a clonal B-cell count  $>0.5 \times 10^9/L$  are referred to as clinical MBL, which is considered a pre-malignant condition. They have a progression rate to CLL requiring therapy of 1%–2% per year. Indeed, virtually all cases of CLL are preceded by an MBL stage [13–17].

The role of immune interactions in MBL remains uncharacterized. While B-cell expansions in patients with advanced CLL are accompanied by immune suppression that restrains antitumor immunity, prior investigations have indicated that T-cell function in MBL deviates only slightly [1,18]. Thus, although immunosuppressive features and T-cell repertoire restrictions are already detectable in MBL and evolve toward a

more suppressive profile across the disease stages [18–20], the functional immune cell fraction may play relevant roles in MBL dynamics and in clonal evolution leading to CLL. An understanding of the immune interactions in preleukemic individuals would also be relevant for deciphering molecular mechanisms underlying the natural history of the disease. In this study, we characterized PB CD4<sup>+</sup> cells (including CD4<sup>+</sup> T cells and monocytes) and serum samples of a large cohort of MBL and early-stage CLL patients to elucidate more comprehensively these issues.

## Methods

### Patients and samples

A total of 62 subjects with clinical CLL-like MBL and 56 untreated, early-stage CLL patients (Binet A/Rai 0–I and  $<20 \times 10^9$  clonal B cells/L) were evaluated. Patients were cared for at Hospital del Mar ( $n=50$ ) and Hospital Vall d’Hebron ( $n=11$ ) in Barcelona (Spain) and at Northwell Health ( $n=57$ ) in New York (USA). Additionally, 31 age-matched healthy subjects were studied as controls. No case had evidence of infection at sampling. The main characteristics of the entire cohort are summarized in Table 1. At the end of the study, all MBL cases remained asymptomatic, and none progressed to CLL requiring therapy. The study was performed in accordance with National and International Guidelines (Professional Code of Conduct, Declaration of Helsinki) and approved by the Ethics Committee of Hospital del Mar, Barcelona (2011/4317/I). Fresh PB, cryopreserved PB mononuclear cells (PBMCs), and frozen serum samples were characterized using several methods (Supplementary

**Table 1.** Characteristics of the study cohort at the time of analysis and last follow-up

	Control ( $n=31$ )	MBL ( $n=62$ )	CLL Binet A ( $n=56$ )
Age	64 (42–88)	69 (45–89)	64 (37–89)
Absolute lymphocyte count ( $\times 10^9$ cells/L)	1.7 (0.4–3.2)	5.0 (0.9–10.1)	13.2 (7.9–24.2)
Clonal B-cell count ( $\times 10^9$ cells/L)	NA <sup>a</sup>	2.1 (0.5–4.8)	10.2 (5.8–19.4)
Rai stage	NA	NA	
0			48 (85.7%)
I			8 (14.3%)
Mutated IGHV	NA	48/54 (88.9%)	32/54 (59.3%)
Treated patients	NA	0	11 (19.6%)
Deaths	NA	3 (4.8%)	6 (10.7%)
Follow-up from recruitment (mo)	NA	48 (0–117)	67 (0–143)

NA = not applicable.

Values are expressed as the median (range) or number (%).

<sup>a</sup>Polyclonal B-cell count:  $0.07 \times 10^9$  cells/L (0.04–0.21).

Figure E1, online only, available at [www.exphem.org](http://www.exphem.org)). A portion of the samples were obtained from MARBiobanc (Barcelona, Spain). Data from Northwell Health were collected using REDCap [21].

#### *Cell isolation and RNA extraction for gene expression analyses*

Fresh PB was subjected to Ficoll density gradient centrifugation. Purified CD4<sup>+</sup>CD19<sup>-</sup> (total CD4<sup>+</sup> cells, including CD4<sup>+</sup> T cells and monocytes), CD4<sup>+</sup>CD14<sup>-</sup> (CD4<sup>+</sup> T cells), and CD14<sup>+</sup> cells (monocytes) were isolated from PBMCs based on positive selection methods employing immunomagnetic beads (CD19 Multisort Kit, CD19 MicroBeads, CD4 MicroBeads, and CD14 MicroBeads) and autoMACS technology (Miltenyi Biotec, Bergisch Gladbach, Germany). A flowchart describing all cell isolation procedures for gene expression analyses is provided in Supplementary Figure E2 (online only, available at [www.exphem.org](http://www.exphem.org)). To assess the efficacy of the purification process, 100,000 cells of each sample were analyzed by flow cytometry using anti-CD3 (allophycocyanin [APC]), anti-CD4 (phycoerythrin [PE]), anti-CD14 (fluorescein isothiocyanate [FITC]), and/or anti-CD45 (peridinin chlorophyll–protein cyanine 5.5 [PerCP-Cy5.5]) antibodies (BD Biosciences, San Jose, CA, USA). A purity  $\geq 90\%$  was achieved in all samples, except two MBL cases in whom the purity of total CD4<sup>+</sup> cells was 70%. Purified cells were stored at  $-80^{\circ}\text{C}$  in 1% BME RLT-plus buffer (QIAGEN, Venlo, The Netherlands). RNA was finally extracted according to the RNeasy Plus Mini Kit protocol (QIAGEN).

#### *Gene expression analysis by microarrays*

RNA from total CD4<sup>+</sup> cells was employed for gene expression arrays in 9 healthy controls, 15 MBL individuals, and 14 CLL patients. All samples used for microarray experiments had an RNA integrity number (RIN)  $>7$ . Briefly, 30 ng of total RNA was retrotranscribed into cDNA and amplified (Ovation Pico WTA System V2, NUGEN, Redwood City, CA, USA). The cDNA product was purified (MinElute Reaction Cleanup Kit, QIAGEN), its yield and purity were measured, biotinylated fragments were added to the hybridization cocktail, and it was finally hybridized on GeneChip Human Gene 2.0 ST array (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. Data quality assessment was performed with the Expression Console (Affymetrix) and R (Version 3.1.1). A Robust Multi-array Average (RMA) algorithm, included in the *aroma.affymetrix* package, was used for data normalization [22]. To correct for batch effects, ComBat, implemented in the R package SVA, was employed [23]. Differential expression analysis was performed using the *limma* R package [24]. *p* Values  $< 0.05$  together with a fold change  $|\text{FC}| > 1.2$  cutoff value were used to generate the list of differentially expressed genes. Gene annotations were obtained from the Affymetrix annotation file Human Gene 2.0 ST array (NetAffix Version na34, hg19). The UCSC database was employed (Feb. 2009 hg19, GRCh37) to complement Affymetrix annotations. Microarray data have been deposited in the Gene Expression Omnibus (GEO) database under series accession No. GSE125791 [25]. A gene pathway analysis of the genetic signature of total CD4<sup>+</sup> cells was accomplished using Ingenuity Pathway Analysis (IPA, QIAGEN). Finally,

to gain insight into the differential contribution of monocytes and T cells in gene expression, the BioGPS tool (<http://biogps.org>) was employed.

#### *Gene expression analysis by quantitative RT-PCR*


To confirm the gene expression levels detected by microarrays in total CD4<sup>+</sup> cells, RNA from the same samples (excluding the 2 cases with purities  $<90\%$ ) and from an additional independent cohort consisting of 8 MBL and 5 CLL patients (purity  $\geq 90\%$ , 49 cases in total) was subjected to quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation. To elucidate the different contributions of CD4<sup>+</sup> T cells and monocytes to gene expression, RNA from additional CD14-depleted CD4<sup>+</sup> cells (CD4<sup>+</sup> T cells) and CD14<sup>+</sup> cells (monocytes) was subjected to the same qRT-PCR validation panel (in 4 healthy and 8 MBL individuals; and 3 healthy and 9 MBL individuals, respectively). This panel consisted of 13 selected genes (*CCL2*, *CLU*, *CXCL5*, *DEFA1*, *FGFBP2*, *GZMH*, *ITGAM*, *NEXN*, *NKG7*, *PPBP*, *RAB31*, *TUBB1*, and *VSTM1*; assays detailed in Supplementary Table E1, online only, available at [www.exphem.org](http://www.exphem.org)) significantly upregulated by gene expression arrays and related to inflammation, Th1 cells, and cytotoxic pathways. *GUSB* and *GAPDH* were employed as housekeeping genes. A total of 400 ng of RNA was analyzed in this customized gene panel, using Taqman Low Density Arrays (TLDA, Life Technologies, Foster City, CA) according to the manufacturer's instructions. For qRT-PCR data analysis, outlier replicates, defined by a SD  $>0.5$  and a qRT-PCR threshold cycle ( $C_t$ )  $>40$ , were excluded. The  $\Delta C_t$  measures, defined as the mean of the expression of a studied gene minus the mean of the expression of the selected housekeeping genes, were compared.

#### *Flow cytometry analysis*

Cryopreserved PBMCs from 8 controls, 11 MBL subjects, and 10 CLL patients were assessed. PBMCs were washed and labeled with the following antibodies: anti-CD45 (PerCP-Cy5.5), anti-CD14 (FITC), anti-CD3 (V450), anti-CD4 (PE), anti-CD4 (APC), anti-HLA-DR (PE-Cy7), anti-CXCR3 (PerCP-Cy5.5), anti-perforin (AF488), anti-granzyme B (FITC), anti-PD1 (PE), and anti-CD27 (PE). FVS510 was employed to discriminate viable from nonviable cells, and the Fixation/Permeabilization Solution Kit, to stain intracellular molecules. Isotype controls (PE, PerCP-Cy5.5, PE-Cy7, and APC) and fluorescence-minus-one controls were used to assess antigen expression correctly. All reagents were purchased from BD Biosciences. Data acquisition was performed in a BD FACSCanto II cytometer and analyzed using the FACSDiva software (BD Biosciences). The gating strategy used to define monocytes and CD4<sup>+</sup> T cells and evaluate the expression of the antigens of interest is detailed in Figure 1.

#### *Multiplex cytokine analysis*

In 24 healthy subjects, 40 MBL individuals, and 44 CLL patients, serum levels of 19 cytokines (IL1 $\beta$ , IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL15, IL17A, interferon  $\alpha$  [IFN $\alpha$ ], IFN $\gamma$ , tumor necrosis factor  $\alpha$  [TNF $\alpha$ ], granulocyte macrophage colony-stimulating factor [GM-CSF], CC chemokine



**Figure 1.** Flow cytometry gating strategy. FVS510 was used to select viable cells (1). After gating for singlets (2), CD45<sup>+</sup>CD14<sup>+</sup>CD4<sup>+</sup> cells (monocytes) were selected (3 and 4) and linear mean fluorescence intensity (MFI) values of HLA-DR were registered (5a). The absence of fluorescence for PE-Cy7 on monocytes was confirmed by employing isotype control (5b). On the other hand, CD3<sup>+</sup>CD4<sup>+</sup> cells (CD4<sup>+</sup> T cells) were gated (6). The percentage of CD4<sup>+</sup> T cells that were positive for CXCR3 (7a) and PD1 or negative for CD27 was assessed employing isotype controls (7b), whereas the percentage of CD4<sup>+</sup> T cells that were positive for perforin (8a) and granzyme B was evaluated using fluorescence-minus-one (FMO) controls (8b). In the plots, fluorescence intensity values are transformed into logarithmic scale.

ligand 3 [CCL3], CCL4, CCL19, CXC chemokine ligand 10 [CXCL10], and CXCL11) were quantified using the U-PLEX Platform (Meso Scale Discovery, Rockville, MD), and that of one cytokine (CXCL9) was quantified using human CXCL9/MIG Quantikine ELISA Kit (R&D Systems, Minneapolis,

MN). All determinations were performed in duplicate, and concentrations were reported in picograms per milliliter. To study the potential cytokine interactions, their respective coding genes were obtained, and genomic data were analyzed using IPA.



### Tumor cell survival analysis

Cryopreserved PBMCs from 6 MBL subjects and 5 CLL patients, all of them with mutated IGHV genes, were employed. Purified tumor B cells were isolated based on negative selection methods employing immunomagnetic beads (B-CLL Cell Isolation Kit) and autoMACS technology (Miltenyi Biotec). To assess the purification process efficacy, 100,000 cells of each sample were analyzed by flow cytometry using anti-CD33 (FITC), anti-CD4 (PE), anti-CD20 (PerCP-Cy5.5), and anti-CD5 (APC) antibodies (BD Biosciences). Purity of  $\geq 90\%$  of tumor B cells was achieved for all samples (median: 98.2%, range: 90.1%–99.2%). Additionally, CD14-enriched cell fractions and CD14-depleted PBMCs were obtained using CD14 MicroBeads (Miltenyi Biotec). The same flow cytometry panel was employed to evaluate the percentage of monocytes in the CD14-enriched cell fraction (median: 85.9%, range: 51.3%–95.3%), total PBMCs and CD14-depleted PBMCs (median: 4.7% versus 0.9% respectively,  $p$  value = 0.003). A total of  $1 \times 10^5$  tumor cells were cultured alone or in the presence of  $6 \times 10^5$  cells of the CD14-enriched fraction, in addition to cell cultures of  $1 \times 10^6$  total PBMCs and CD14-depleted PBMCs. Cells were resuspended in 200  $\mu\text{L}$  of RPMI-1640 medium supplemented with 1% fetal bovine serum (FBS), L-glutamine (4 mmol/L), penicillin (100 U/mL), and streptomycin (100  $\mu\text{g}/\text{mL}$ ) in MW96 assay plates (Corning Inc., Corning, NY). Cells were then centrifuged at 200g for 4 min and cultured for 24 hours at 37°C and 5%  $\text{CO}_2$ . After that period, cells were washed and labeled with anti-CD33 (FITC), anti-CD4 (PE), anti-CD20 (PerCP-Cy5.5), anti-CD5 (APC), and FV5510, which allowed the identification of two subpopulations (viable and nonviable cells) within the tumor cell clone in all included patients, as illustrated in Supplementary Figure E3 (online only, available at [www.exphem.org](http://www.exphem.org)). Data acquisition was performed in a BD FACSCanto II cytometer and analyzed using FlowJo (FlowJo LLC, Ashland, OR). The effect of monocytes on tumor viability was assessed as the difference between the viability of tumor cells cultured with the CD14-enriched cell fraction and the viability of tumor cells cultured alone.

### Statistical analysis

The  $t$  test and Mann–Whitney  $U$  test were used to estimate the statistical significance of the differences identified between independent groups, whereas the results of the tumor cell survival analysis comparing different conditions within the same participant were evaluated using the Wilcoxon test. Linear regression analysis and Spearman correlations were calculated to evaluate the relationship between gene expression intensity and protein expression by flow cytometry.  $p$  Values  $< 0.05$  were considered to indicate significance. Statistical analyses were performed using R, SPSS version 22, and SAS version 9.3.

## Results

### Increased inflammatory signature in MBL orchestrated mainly by monocytes


The profiles identified by gene expression arrays in total  $\text{CD4}^+$  mononuclear cells were compared between MBL subjects and controls. Considering only cases with a purity  $\geq 90\%$ , a total of 1,786 genes were differentially expressed in MBL (953 overexpressed and 833

underexpressed). The most differentially expressed genes are detailed in Supplementary Table E2 (online only, available at [www.exphem.org](http://www.exphem.org)). Significant overexpression in 11 of 13 gene determinations (85%) was corroborated by qRT-PCR analysis and was maintained when only IGHV-mutated MBL individuals were considered (Supplementary Table E1).

A gene pathway analysis of the genetic signature observed in total  $\text{CD4}^+$  cells from MBL individuals was performed employing IPA, which recognized 1,330 differentially expressed genes between MBL and controls. Significant canonical pathways predicted to be activated ( $Z$  score  $\geq 2$ ) included several functions in which monocytes and macrophages are typically involved, such as  $\text{Fc}\gamma$  receptor-mediated phagocytosis, the role of pattern recognition receptors (PRR) in pathogen recognition, the acute phase response, and TREM1 signaling pathways. Inflammasome, chemokine, and IL8 signaling pathways were also predicted to be activated (Figure 2; Supplementary Tables E3 and E4, online only, available at [www.exphem.org](http://www.exphem.org)). As expected, BioGPS analysis supported a myeloid contribution for the differentially expressed genes of these pathways (Supplementary Table E5, online only, available at [www.exphem.org](http://www.exphem.org)). These results were maintained when only IGHV-mutated MBL subjects were considered (Supplementary Table E4).

Additionally, an upstream analysis predicted some genes coding for receptors and co-receptors involved in pathogen recognition ( $\text{TLR2}$ ,  $\text{TLR7/8}$ , or  $\text{CD14}$ ) and pro-inflammatory cytokines ( $\text{IFNG}$ ,  $\text{TNF}$ ,  $\text{IL1B}$ ,  $\text{IL17A}$ , or  $\text{IL18}$ ) as activated (Supplementary Table E6, online only, available at [www.exphem.org](http://www.exphem.org)). Numerous functions related to cell migration and inflammation were also predicted to be activated (Supplementary Table E7, online only, available at [www.exphem.org](http://www.exphem.org)).

This increased inflammatory drive detected in MBL was also supported by serum cytokine analysis, which revealed that levels of 11 of 20 measured cytokines ( $\text{IL5}$ ,  $\text{IL6}$ ,  $\text{IL8}$ ,  $\text{IL10}$ ,  $\text{IFN}\gamma$ ,  $\text{TNF}\alpha$ ,  $\text{CCL3}$ ,  $\text{CCL4}$ ,  $\text{CXCL9}$ ,  $\text{CXCL10}$ , and  $\text{CXCL11}$ ) were significantly higher in MBL individuals compared with controls (Table 2). Of note, 5 of these ( $\text{IL5}$ ,  $\text{IL6}$ ,  $\text{IL8}$ ,  $\text{IFN}\gamma$ , and  $\text{TNF}\alpha$ ) are involved in the HMGB1 signaling pathway, which induces the release of pro-inflammatory cytokines, and was predicted to be activated by IPA ( $p$  value  $< 0.001$ ,  $Z$  score: 2.2). In line with the aforementioned, an upstream analysis predicted activation of Toll-like receptors (TLR) such as  $\text{TLR3}$ ,  $\text{TLR4}$ , and  $\text{TLR9}$  ( $p$  value  $< 0.001$ ,  $Z$  score: 2.4, 2.4, and 2, respectively), which can be stimulated through HMGB1 interaction. Notably, when we repeated the analysis considering IGHV mutational status (Supplementary Table E8, online only, available at [www.exphem.org](http://www.exphem.org)), significantly increased levels of 10 and 4



**Figure 2.** Differentially expressed genes and pathways in total CD4<sup>+</sup> cells of MBL and CLL patients. Gene expression intensity is represented as log<sub>2</sub> values centered and scaled. Detailed information on the enumerated genes is provided in Supplementary Table E3. *CTR*=healthy controls; *PRR*=pattern recognition receptors; *APR*=acute phase response; *S.*=signaling.

**Table 2.** Serum cytokine levels of healthy controls, MBL individuals, and CLL patients

Cytokine	Control (n = 24)		MBL (n = 40)		CLL (n = 44)		p Value	
	Median	Range	Median	Range	Median	Range	MBL vs. control	CLL vs. MBL
IL-1β	0.26	0.07–5.85	0.35	0.07–124.27	0.47	0.07–114.13	0.475	0.061
IL-2	1.49	0.44–8.07	1.49	0.44–11.80	1.66	0.44–16.49	0.633	0.273
IL-4	0.21	0.06–0.79	0.21	0.06–40.67	0.08	0.06–1.34	0.875	0.210
IL-5	1.44	0.45–4.97	2.01	0.52–4.42	1.51	0.45–4.19	0.004 <sup>a</sup>	0.005 <sup>a</sup>
IL-6	2.04	1.16–151.09	3.62	1.16–1431.63	2.80	0.34–1689.05	0.021 <sup>a</sup>	0.080
IL-8	22.05	6.15–5216.03	238.01	7.21–6810.22	20.73	4.00–8807.27	0.980	0.019 <sup>a</sup>
IL-10	0.74	0.39–1.66	0.93	0.39–3.74	0.88	0.39–5.03	0.017 <sup>a</sup>	0.451
IL-12	1.07	0.60–3.57	1.07	0.60–18.42	1.07	0.60–3.08	0.299	0.358
IL-15	3.21	1.03–7.65	2.92	0.51–7.09	2.88	0.51–7.92	0.787	0.865
IL-17A	2.51	0.51–13.14	2.52	0.51–21.39	2.52	0.51–16.69	0.199	0.895
IFNα	1.23	0.45–6.58	1.98	0.45–7.95	2.20	0.45–14.91	0.286	0.913
IFNγ	11.24	3.30–42.08	16.69	1.44–151.14	13.24	3.30–69.33	0.014 <sup>a</sup>	0.026 <sup>a</sup>
TNFr	2.25	0.50–29.74	4.99	1.30–69.19	3.30	0.70–28.21	0.140	0.149
GM-CSF	0.23	0.09–1.05	0.42	0.09–1.51	0.24	0.09–0.88	0.151	0.590
CCL3	22.67	17.80–2925.30	46.00	19.05–2913.37	39.13	4.61–6427.70	0.001 <sup>a</sup>	0.395
CCL4	114.53	56.66–1753.44	176.57	76.92–2358.09	151.61	29.75–2915.75	0.012 <sup>a</sup>	0.275
CCL19	109.36	52.26–449.53	131.95	3.17–871.66	108.35	4.53–1561.50	0.071	0.078
CXCL9	70.98	15.70–1044.45	165.53	15.70–1166.00	151.78	15.70–1982.50	0.003 <sup>a</sup>	0.964
CXCL10	188.10	102.88–985.02	325.21	10.73–1904.78	230.79	5.25–735.04	0.016 <sup>a</sup>	0.029 <sup>a</sup>
CXCL11	32.37	13.15–122.40	47.05	10.60–213.10	53.69	8.09–315.39	0.010 <sup>a</sup>	0.844

<sup>a</sup>All determinations were performed in duplicate. Cytokine values are reported in picograms per milliliter (pg/mL).

<sup>a</sup>Significant p values (<0.05).


cytokines were disclosed in MBL subjects with mutated and unmutated IGHV genes compared with controls, respectively. The small number of MBL cases with unmutated IGHV genes (n=4) may account for the reduced significant differences in this group, which actually displayed very similar high levels of those cytokines significantly increased in IGHV-mutated MBL. Consequently, no significant differences were disclosed between both MBL groups.

*Decreased inflammatory signature in early-stage CLL, especially IGHV-mutated patients*

Next, gene expression profiles of total CD4<sup>+</sup> mononuclear cells (purity ≥90%) were compared between CLL patients and controls and between CLL and MBL patients. In all, 1,039 genes were differentially expressed in the CLL-versus-control comparison (460 overexpressed and 579 underexpressed) and 806 in the CLL-versus-MBL comparison (398 overexpressed and 408 underexpressed). The most differentially expressed genes are detailed in Supplementary Table E2. The qRT-PCR analysis corroborated significant differential expression in 6 gene determinations (Supplementary Table E1).

IPA recognized 742 differentially expressed genes for CLL versus control; however, significant activated canonical pathways were not detected. Some signs of functional immunity were predicted (such as CD28 or interferon activation and increased binding and phagocytosis of cells; Supplementary Table E9, online only, available at [www.exphem.org](http://www.exphem.org)), although to a much lesser extent compared with MBL versus control. This decreased inflammation in early-stage CLL was also corroborated by cytokine analysis in serum, which revealed only 2 (CXCL9 and CXCL11) of the 20 measured cytokines to be significantly more elevated in CLL patients compared with controls (Table 2).

Concerning CLL versus MBL, 598 differentially expressed genes were recognized by IPA, which revealed phospholipases and IL8 signaling pathways as significantly decreased in CLL compared with MBL (Figure 2; Supplementary Tables E3 and E4), in addition to upstream inhibition of IFNG, IL5, TNF, or TLR7 and decreased functions related to cell migration and lipid metabolism (Supplementary Table E10, online only, available at [www.exphem.org](http://www.exphem.org)). The reduced immune activity observed in early-stage CLL compared with MBL was specifically confirmed in circulating monocytes when HLA-DR expression was analyzed by flow cytometry. Thus, monocyte HLA-DR expression was significantly reduced in CLL compared with MBL, both when considering all patients or when restricting the analysis to IGHV mutated patients (Figure 3A; Supplementary Figure E4, Supplementary Table E11, online only, available at [www.exphem.org](http://www.exphem.org)).



**Figure 3.** Flow cytometry analysis. MFI of HLA-DR was assessed on monocytes (A), and the percentages (%) of CD4<sup>+</sup> T cells that were positive for CXCR3 (B), perforin (C), granzyme B (D), and PD1 (E) or negative for CD27 (F) were registered. Significant *p* values are indicated: \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001. CTR=healthy controls.

Finally, serum levels of four cytokines (IL5, IL8, IFN $\gamma$ , and CXCL10) were significantly decreased in CLL compared with MBL (Table 2).


Interestingly, when CLL cases were separated into two groups according to IGHV mutation status, differences were underscored in MBL versus CLL patients with mutated IGHV (M-CLL, <98% germline identity). In this sense, M-CLL cases had decreased levels of IL4, IL5, IL8, IFN $\gamma$ , CCL3, and CXCL10 compared with MBL. Remarkably, four of these cytokines (IL4, IL5, IL8, and IFN $\gamma$ ) are involved in the pro-inflammatory HMGB1 pathway, which was predicted to be inhibited in M-CLL compared with MBL (*p* value < 0.001, *Z* score: -2). Nonetheless, CLL patients with unmutated IGHV (U-CLL,  $\geq$ 98% germline identity) only manifested significant decreased levels of IL5 and CCL19 and increased levels of IL1 $\beta$  compared with MBL (Figure 4). As levels of the aforementioned cytokines were similar for MBL patients with mutated and unmutated IGHV genes, comparisons with CLL groups did not significantly differ when IGHV mutational

status of MBL was considered, and the loss of statistical significance in some comparisons could be attributed to the more reduced number of cases in both MBL groups (Supplementary Table E8).

#### Similar increase in Th1 and cytotoxic CD4<sup>+</sup> T cells in MBL and early-stage CLL

A detailed analysis of the differentially expressed genes between groups also disclosed an upregulation of genes previously associated with Th1 cells [26] (*DUSP2*, *MAP3K8*, *PLEK*, *CFH*, *TARP*, *IL18RAP*, *GNLY*, *GZMH*, or *NKG7*) in total CD4<sup>+</sup> cells of both MBL and CLL compared with controls. In addition, genes related to cytotoxic pathways (*GZMB*, *GZMH*, *GNLY*, *FGFBP2*, *FCRL6*, and *NKG7*) were also upregulated in both entities compared with controls (Figure 2; Supplementary Table E3). If the two MBL cases with a total CD4<sup>+</sup> cell purity of 70% were considered, *PRF1* (coding for perforin) was also significantly overexpressed in MBL versus control (FC = 1.64) and CLL versus control (FC = 1.55).





**Figure 4.** Serum cytokine levels in MBL and CLL patients with mutated IGHV (M-CLL) or unmutated IGHV (U-CLL). All determinations were performed in duplicate. Cytokine values (pg/mL) represented on the y axis were transformed into logarithmic scale. Only those cytokines with significant differences in at least one comparison are shown. Significant  $p$  values are indicated: \* $p < 0.05$ , \*\* $p < 0.01$ .


BioGPS analysis pointed to a T-cell contribution for most of the differentially expressed genes associated with Th1 cells and cytotoxicity, the latter exhibiting statistical significance only for CD8<sup>+</sup> T cells (Supplementary Table E5). This is not surprising considering that cytotoxic CD4<sup>+</sup> T cells are closely related to CD8<sup>+</sup> T cells. Nonetheless, when we analyzed RNA from CD14-depleted CD4<sup>+</sup> cells (CD4<sup>+</sup> T cells) and CD14<sup>+</sup> cells (monocytes) of MBL patients using the qRT-PCR panel previously described, significant overexpression of cytotoxic genes (*GZMH*, *FGFBP2* and *NKG7*) was observed only for CD4<sup>+</sup> T cells (Supplementary Table E12, online only, available at [www.exphem.org](http://www.exphem.org)), which confirms that CD4<sup>+</sup> T cells account for the cytotoxic gene expression signature in MBL.

Flow cytometry analyses verified the similar increase in Th1 and cytotoxic CD4<sup>+</sup> T cells in both entities. The percentages of CD4<sup>+</sup> T cells that were positive for CXCR3, generally accepted as a marker of Th1 cells [27,28], and for the cytotoxic proteins perforin and granzyme B were higher in MBL and CLL patients compared with controls. Moreover, increased percentages of PD1<sup>+</sup> (exhausted) or CD27<sup>-</sup> (effector) CD4<sup>+</sup> T cells were also detected in both entities. Nonetheless, statistical significance was achieved only for perforin (MBL versus control) and for CXCR3 and PD1 (MBL and CLL versus control), which was maintained when only IGHV-mutated patients were considered (Figure 3B–F; Supplementary Table E11).

For those cases that were assessed by gene expression arrays and flow cytometry ( $n = 13$ ), a significantly positive correlation was observed between *PRF1* and *GZMB* expression and the percentage of CD4<sup>+</sup> T cells that were positive for perforin ( $\rho = 0.62$ ,  $p$  value = 0.024) and granzyme B ( $\rho = 0.81$ ,  $p$  value = 0.001), respectively.

#### *Tumor-supporting effects of monocytes are similarly observed in MBL and early-stage CLL*

To gain insight into the possible functional consequences of the monocyte gene expression signature on tumor survival, different cell cultures were performed. After 24 hours, MBL and CLL patients had a similar percentage of viable tumor cells (median: 64.6% versus 68% respectively,  $p$  value = 0.931) and also a similar effect of monocytes on tumor viability (median increase: 10.1% versus 9.7% respectively,  $p$  value = 0.537). Related to the aforementioned finding, the viability of tumor cells from MBL individuals was increased when they were cultured in the presence of the CD14-enriched cell fraction (median: 64.6% versus 79.3%,  $p$  value = 0.046), and similar results were observed for CLL (median: 68% versus 83.9%,  $p$  value = 0.043). In line with this, CD14<sup>+</sup> cell depletion from PBMCs led to decreased tumor cell viability in CLL (median: 88.7% versus 71.6%,  $p$  value = 0.043), and a similar trend was observed in MBL (median: 85.8 versus 75.6%,  $p$  value = 0.075) (Figure 5).



**Figure 5.** Tumor cell survival analysis. All cell cultures were incubated for 24 hours. To evaluate the viability of tumor cells, clonal B cells were cultured alone (A). The effect of monocytes on tumor viability was assessed as the viability of tumor cells cultured with CD14-enriched cells minus the viability of tumor cells cultured alone (B). For each subject, variations in tumor viability between the two previous conditions are shown (C), as is the viability of tumor cells within total PBMCs or CD14-depleted PBMCs (D).

## Discussion

Several studies in CLL have reported a dysfunctional microenvironment with tumor-supportive effects [4–9,29,30]. In the present study, signs of immune stimulation were found in MBL, which exhibited an increased inflammatory signature corroborated by different techniques. Notably, prior studies were focused mainly on more advanced stages of the disease, where independent malignant proliferation is accompanied by severe immunosuppression. The lack of previous studies that comprehensively characterized the immune system in MBL, including molecular pathways of monocytes, may explain why this early inflammatory signature had not been revealed yet.

Remarkably, MBL exhibited activation of several functions related to pathogen recognition by innate immune cells (e.g., monocytes). Among them, phagocytosis and stimulation of PRR such as TLR, which triggers the overexpression of pro-inflammatory genes [31], were highlighted. Similarly, a role was noted for HMGB1, which can bind to PRR to mediate cytokine production [32]. Among these cytokines, IL8 is released and acts as an important mediator of the immune response. Of note, both IL8 serum levels and the IL8 signaling pathway in total CD4<sup>+</sup> cells were increased in our MBL cohort. Our results were also validated in an independent proteomic study, which revealed especially increased serum levels of IL8 in MBL patients compared with controls, in addition to an activation of the HMGB1 signaling pathway (data not shown). This inflammatory axis of MBL could be initiated on monocyte PRR stimulation by pathogens that may be related to the development of the disease. A role for self-antigens that can bind PRR and activate B cells was also reported [33]. In this sense, the maintenance of a pro-inflammatory environment, such as

that identified here in preleukemic individuals, could contribute to neoplastic transformation. These results are in line with previous investigations suggesting a key role of self or foreign antigens in CLL development [2,20,34–36]. In this regard, the presence of immune stimulation was described several years before CLL diagnosis [37], and increased susceptibility to clonal expansions was associated with the development of the disease [38].

Strikingly, we also found that the aforementioned inflammatory drive was reduced in early-stage CLL. Specifically, IPA predicted decreased IL8, IL5, and IFN $\gamma$  signaling pathways in CLL compared with MBL, and the levels of these three cytokines were also significantly diminished in serum of CLL patients compared with that of MBL individuals. The expression of HLA-DR on monocytes, which could be considered a marker of immune activation as it is essential for antigen presentation that initiates a specific immune response, was also significantly decreased in CLL compared with MBL. These differences could be a consequence of a reduced function of pro-inflammatory monocytes and/or to a decreased percentage of these monocyte subsets (which express higher HLA-DR levels compared with classical monocytes) in CLL [39,40]. Therefore, the distinct monocyte subsets should be isolated and further characterized to clarify their differential contributions in MBL and CLL pathogenesis. These as yet unknown findings, together with the gene expression and cytokine results revealing augmented pro-inflammatory pathways in MBL, may reflect not only increased immunosuppression with tumor progression but also a stimulated immune system in MBL.

Additionally, the inflammatory signature of MBL subjects was especially reduced in M-CLL. In line with this, a different ongoing proteomics analysis predicted

a significant inhibition of IL8 and HMGB1 signaling pathways in M-CLL compared with MBL, as demonstrated by cytokine immunoassays in the present study. The ongoing proteomic analyses also support that M-CLL patients rather than U-CLL patients may be responsible for the reduction of the inflammatory drive observed in MBL (unpublished results). Clonal cells observed in U-CLL patients are more dependent on environmental prosurvival signals [41] and, therefore, interact more actively with the immune environment than M-CLL clones. These interactions may imply cognate antigens presented by HLA molecules, which may account for our previous observations concerning a reduced monocyte HLA-DR expression in M-CLL. Nonetheless, MBL subjects with mutated IGHV genes significantly overexpressed monocyte HLA-DR compared with M-CLL, suggesting that another mechanism rather than the stimulation by the anergic and small B-cell clone may explain monocyte activation in MBL. On the other hand, B-cell receptor (BCR) signaling, which can stimulate production of cytokines such as IL8 and CCL3 [42,43], is more frequent in U-CLL. In our study, levels of both cytokines were significantly decreased in M-CLL compared with MBL, but similar increased levels were observed in U-CLL and in MBL subjects independently of their IGHV mutational status, suggesting that this increased inflammatory signature is MBL specific. In this regard, BCR-dependent cytokine production by malignant cells may depend on their capacity to interact with the immune environment, which may be restricted in M-CLL and in the majority of MBL cases as 75%–80% of them manifest mutated IGHV [15,44]. Therefore, the increased inflammatory molecules observed in MBL may be actively produced by the immune environment rather than by the emerging and relatively small B-cell clone. The gene expression results of circulating CD4<sup>+</sup> cells in the present study showing increased inflammatory pathways in MBL also support this hypothesis.

We have also reported that co-cultures of clonal B cells from MBL individuals with autologous CD14-enriched cells enhanced tumor cell viability. This finding suggests that the monocyte gene program and the related overexpressed inflammatory genes in MBL may not be globally a consequence of antitumor effects of monocytes. In this sense, tumor-supporting effects of the monocyte/macrophage lineage were previously reported in CLL [30,45–47], and our current findings would extend this protective role to MBL. In addition, effects of monocytes on tumor survival were similarly observed in MBL and early-stage CLL. As the former exhibited increased inflammatory features, these may therefore be related to an increased antigen stimulation potentially associated with recent malignant transformation rather than to increased tumor-supporting

effects of monocytes in MBL. However, the possibility that some of these inflammatory molecules act as tumor prosurvival signals cannot be discarded. It is also worth mentioning that in healthy conditions, macrophages promoted BCR-stimulated B-cell proliferation [48] and monocytes exerted supporting effects on normal B-cell survival [49]. In our experiments, monocytes from MBL and CLL patients increased normal B-cell viability (median: 60% in total PBMCs versus 40.7% in CD14-depleted PBMCs,  $p$  value = 0.043), which also suggests that supporting interactions between monocytes and B cells are not unique to tumor B cells. Therefore, culturing monocytes from healthy controls, MBL subjects, and CLL patients together with the same tumor B-cell clone would be helpful in clarifying if the differences in the inflammatory features that we observed among the three groups could be attributed to differences in tumor-supporting effects of monocytes.

Our findings also suggest that CD4<sup>+</sup> T cells of MBL and early-stage CLL are Th1 biased. We observed upregulated Th1 genes [26] and increased CXCR3<sup>+</sup>CD4<sup>+</sup> T cells, generally accepted as Th1 cells [27,28]. In addition, MBL individuals displayed augmented serum levels of IFN $\gamma$ , CXCL9-11, IL8, or TNF $\alpha$ , which are related to a Th1-monocytic response. As far as we know, this is the first time that a role for CD4<sup>+</sup> Th1 cells is described in MBL, although prior investigations in CLL suggested a Th2 polarization [4,50]. Nonetheless, other studies described a Th1 dominance in early stages of the disease [51], which is in accord with our results. Remarkably, Th1 cells can interact with monocytes/macrophages to induce a specific antitumor response in B-cell tumors [52], and a recent study in CLL revealed that activation of Th1 immunity was associated with clinical response to lenalidomide [53]. Tumoricidal effects of macrophages were also described in a mouse model of the disease [54]. Thus, the Th1-monocytic features that we observed in MBL could potentially restrain malignant expansions. However, when we cultured tumor cells together with the rest of PBMCs, increased tumor viability was observed compared with the same cell cultures without CD14<sup>+</sup> cells, suggesting that interactions between T cells and monocytes may confer protective rather than antitumor roles in MBL and early-stage CLL.

In addition, we identified increased CD4<sup>+</sup> T cells with cytotoxic properties similarly in both MBL and early-stage CLL. These cytotoxic features were specifically confirmed in CD14-depleted CD4<sup>+</sup> T cells of MBL subjects by qRT-PCR, and in CD4<sup>+</sup> T cells of MBL and CLL patients, by flow cytometry. Additionally, our MBL group had the higher median percentage of effector CD27<sup>-</sup>CD4<sup>+</sup> T cells. In line with this, a recent study reported increased levels of CD27<sup>-</sup>CD4<sup>+</sup> T cells mainly in MBL, and augmented CD27<sup>-</sup>granzyme B<sup>+</sup>CD4<sup>+</sup> T cells throughout all disease stages, including MBL [55]. Increased frequencies of CD4<sup>+</sup> T

cells expressing perforin had not been described in MBL before, although it is not surprising taking into account that perforin synergizes with granzymes in the same cytotoxic pathways. Other investigations also described cytotoxic CD4<sup>+</sup> T cells in CLL [56], which were able to kill clonal B cells [57]. All these findings emphasize the nonexclusive role of the immune environment in supporting clonal B-cell survival, although the global effect in MBL and early-stage CLL may rather be tumor supporting, as suggested by the cell culture assays of this study. As previously highlighted, isolation of the different CD4<sup>+</sup> T-cell and monocyte subsets is mandatory to definitely clarify their specific effects on tumor development.

Taken together, we described an increased inflammatory response in MBL, orchestrated mainly by monocytes, that lessens in early-stage CLL. The pro-inflammatory signature identified in MBL could represent an active role for self/foreign antigen stimulation in this pre-leukemic stage, potentially related to recent malignant transformation. Conversely, the possibility that these inflammatory molecules are associated with tumor-supporting effects of monocytes cannot be discarded. These findings offer novel insights into the very early stages of the disease, which will allow the development of future investigations addressed to completely understanding its natural history and, ultimately, to developing pre-emptive strategies for CLL management.

### Acknowledgments

The authors thank all patients and healthy volunteers for their participation in this study and Xavier Duran for statistical support. GB was funded by a grant from Fundació La Caixa and Fundación Española de Hematología y Hemoterapia (FEHH-Janssen). This work has been supported by the following grants: [PI11/1621](#), [PI15/437](#) and [FEDER \(PT13/0010/0005\)](#), Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness; “Xarxa de Bancs de tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC); and [2014/SGR585](#) and [2017/SGR437](#) from Generalitat de Catalunya.

### Conflict of interest disclosure

The authors have no financial conflicts of interest.

### References

1. te Raa GD, Tonino SH, Remmerswaal EB, et al. Chronic lymphocytic leukemia specific T cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. *Leuk Lymphoma*. 2012;53:2321–2325.
2. Vardi A, Vlachonikola E, Karypidou M, et al. Restrictions in the T cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements. *Leukemia*. 2017;31:1555–1561.
3. Farace F, Orlanducci F, Dietrich PY, et al. T cell repertoire in patients with B chronic lymphocytic leukemia: evidence for multiple in vivo T cell clonal expansions. *J Immunol*. 1994;153:4281–4290.
4. Görgün G, Holderried TA, Zahrieh D, Neuberger D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. *J Clin Invest*. 2005;115:1797–1805.
5. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. *J Clin Invest*. 2008;118:2427–2437.
6. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. *Blood*. 2013;121:2704–2714.
7. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T cell exhaustion but retain capacity for cytokine production. *Blood*. 2013;121:1612–1621.
8. Palma M, Gentilcore G, Heimersson K, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. *Haematologica*. 2017;102:562–572.
9. Maffei R, Bulgarelli J, Fiorcari S, et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. *Haematologica*. 2013;98:1115–1123.
10. Yan XJ, Dozmorov I, Li W, et al. Identification of outcome-related cytokine clusters in chronic lymphocytic leukemia. *Blood*. 2011;118:5201–5210.
11. Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1 $\alpha$ ) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. *Blood*. 2011;117:1662–1669.
12. Wierda WG, Johnson MM, Do KA, et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. *Br J Haematol*. 2003;120:452–456.
13. Rawstron AC, Bennett FL, O’Connor SJ, et al. Monoclonal B lymphocytosis and chronic lymphocytic leukemia. *N Engl J Med*. 2008;359:575–583.
14. Landgren O, Albitar M, Ma W, et al. B cell clones as early markers for chronic lymphocytic leukemia. *N Engl J Med*. 2009;360:659–667.
15. Vardi A, Dagklis A, Scarfò L, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. *Blood*. 2013;121:4521–4528.
16. Strati P, Shanafelt TD. Monoclonal B cell lymphocytosis and early stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. *Blood*. 2015;126:454–462.
17. Scarfò L, Dagklis A, Scielzo C, Fazi C, Ghia P. CLL-like monoclonal B cell lymphocytosis: are we all bound to have it? *Semin Cancer Biol*. 2010;20:384–390.
18. Rissiek A, Schulze C, Bacher U, et al. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T cells in chronic lymphocytic leukemia. *Int J Cancer*. 2014;135:2370–2379.
19. D’Arena G, Rossi G, Minervini MM, et al. Circulating regulatory T cells in “clinical” monoclonal B lymphocytosis. *Int J Immunopathol Pharmacol*. 2011;24:915–923.
20. Blanco G, Vardi A, Puiggros A, et al. Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. *OncImmunity*. 2018;7:e1432328.
21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377–381.



22. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics*. 2003;4:249–264.
23. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics*. 2007;8:118–127.
24. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015;43:e47.
25. National Center for Biotechnology Information. Gene expression omnibus. Available at: <http://www.ncbi.nlm.nih.gov/geo>. Accessed March 30, 2020.
26. Ono C, Yu Z, Kasahara Y, Kikuchi Y, Ishii N, Tomita H. Fluorescently activated cell sorting followed by microarray profiling of helper T cell subtypes from human peripheral blood. *PLoS One*. 2014;9:e111405.
27. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. *J Exp Med*. 1998;187:129–134.
28. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. *J Clin Invest*. 1998;101:746–754.
29. Brusa D, Serra S, Coscia M, et al. The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. *Haematologica*. 2013;98:953–963.
30. van Attekum MHA, Terpstra S, Slinger E, et al. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. *Oncogene*. 2017;36:3651–3660.
31. Stevens WB, Netea MG, Kater AP, van der Velden WJ. Trained immunity: consequences for lymphoid malignancies. *Haematologica*. 2016;101:1460–1468.
32. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. *Proc Natl Acad Sci USA*. 2010;107:11942–11947.
33. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. *J Clin Invest*. 2015;125:2194–2202.
34. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. *J Clin Invest*. 1998;102:1515–1525.
35. Ten Hacken E, Gounari M, Ghia P, Burger JA. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. *Leukemia*. 2019;33:287–298.
36. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. *Blood*. 2008;111:3838–3848.
37. Tsai HT, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. *Blood*. 2009;114:4928–4932.
38. Glenn MJ, Madsen MJ, Davis E, et al. Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees. *Blood Cancer J*. 2019;9:25.
39. Thomas GD, Hamers AAJ, Nakao C, et al. Human blood monocyte subsets: a new gating strategy defined using cell surface markers identified by mass cytometry. *Arterioscler Thromb Vasc Biol*. 2017;37:1548–1558.
40. Mukherjee R, Barman PK, Thatoi PK, et al. Non-classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematosus. *Sci Rep*. 2015;5:13886.
41. Coscia M, Pantaleoni F, Riganti C, et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. *Leukemia*. 2011;25:828–837.
42. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurse-like cell cocultures and after BCR stimulation. *Blood*. 2009;113:3050–3058.
43. Pede V, Rombout A, Vermeire J, et al. Expression of ZAP70 in chronic lymphocytic leukaemia activates NF- $\kappa$ B signalling. *Br J Haematol*. 2013;163:621–630.
44. Morabito F, Mosca L, Cutrona G, et al. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: a comparison of cellular, cytogenetic, molecular, and clinical features. *Clin Cancer Res*. 2013;19:5890–5900.
45. Reinart N, Nguyen PH, Boucas J, et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. *Blood*. 2013;121:812–821.
46. Galletti G, Scielzo C, Barboglio F, et al. Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression. *Cell Rep*. 2016;14:1748–1760.
47. Galletti G, Caligaris-Cappio F, Bertilaccio MTS. B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia. *Leukemia*. 2016;30:2293–2301.
48. Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage- and dendritic cell-dependent regulation of human B cell proliferation requires the TNF family ligand BAFF. *Blood*. 2003;101:4464–4471.
49. Mueller CG, Boix C, Kwan WH, et al. Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation. *J Leukoc Biol*. 2007;82:567–575.
50. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. *Blood*. 2001;97:256–263.
51. Podhorecka M, Dmoszynska A, Rolinski J, Wasik E. T type 1/ type 2 subsets balance in B cell chronic lymphocytic leukemia—the three-color flow cytometry analysis. *Leuk Res*. 2002;26:657–660.
52. Haabeth OA, Lorvik KB, Hammarström C, et al. Inflammation driven by tumour-specific Th1 cells protects against B cell cancer. *Nat Commun*. 2011;2:240.
53. Aue G, Sun C, Liu D, et al. Activation of Th1 immunity within the tumor microenvironment is associated with clinical response to lenalidomide in chronic lymphocytic leukemia. *J Immunol*. 2018;201:1967–1974.
54. Wu QL, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. *J Immunol*. 2009;182:6771–6778.
55. Simões C, Silva I, Carvalho A, et al. Quantification and phenotypic characterization of peripheral blood V $\delta$ 1<sup>+</sup> T cells in chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. *Cytometry B Clin Cytom*. 2019;96:164–168.
56. Porakishvili N, Roschupkina T, Kalber T, et al. Expansion of CD4<sup>+</sup> T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). *Clin Exp Immunol*. 2001;126:29–36.
57. Porakishvili N, Kardava L, Jewell AP, et al. Cytotoxic CD4<sup>+</sup> T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. *Haematologica*. 2004;89:435–443.